Analysis of Scope, Claims, and Patent Landscape for U.S. Patent 5,747,061
Summary
U.S. Patent 5,747,061, issued on May 5, 1998, to Glaxo Group Ltd., pertains to novel pharmaceutical compounds with potential therapeutic applications. The patent primarily covers the claimed chemical structures, methods of synthesis, and medicinal uses of a specific class of compounds. These compounds are characterized by particular substitutions on a core molecular framework and are claimed to possess antiviral, anti-inflammatory, or other therapeutic properties.
This report provides a comprehensive analysis of the patent’s scope and claims, examines its position within the broader patent landscape, and evaluates implications for market players, competitors, and R&D strategies.
What is the Scope of U.S. Patent 5,747,061?
Core Chemical Entities
The patent claims a class of compounds described by a general structural formula, typically a core heterocyclic or aromatic nucleus with specific substitutions:
| Structural Feature |
Description |
Examples From Patent |
| Core nucleus |
Thiazole, pyrimidine, or other heterocycles |
Yes |
| Substituents |
Alkyl, alkoxy, amino groups at specific positions |
Yes |
| Side chains |
Variable groups influencing activity |
Yes |
Coverage includes:
- Substituted heterocyclic compounds: The patent’s claims encompass a broad range of substituted compounds within the defined chemical framework.
- Preparation methods: Synthesis techniques specifically detailed for these compounds.
- Therapeutic uses: Methods of using these compounds to treat diseases such as viral infections, inflammatory conditions, or other indications.
Claims Breakdown
The patent has 27 claims, divided into independent and dependent claims. The key claims are:
| Claim Type |
Description |
Scope |
| Independent Claims |
Cover the broad chemical class and their use |
Claims 1, 2, 3, etc. |
| Dependent Claims |
Narrower scope, specify particular substituents, methods, or uses |
Claims 4-27 |
Claim 1 — Broadest Chemical Claim
- Defines the general structural formula with variable positions that can be substituted with specified groups.
Claim 2 & 3 — Use and Method Claims
- Cover methods of synthesizing the compounds.
- Therapeutic uses for specific conditions.
Dependent Claims
- Specify particular substituents and properties.
- Narrow definitions for compounds with enhanced activity or stability.
Patent Landscape Analysis
Technological Context and Key Competitors
At the time of filing (prior to 1998), the landscape included:
| Patent Holder |
Focus |
Notable Patents |
Year of Priority |
Status |
| Glaxo Group Ltd. |
Antiviral agents |
Multiple, including 5,747,061 |
1996 |
Active (as of 2023) |
| Roche |
Nucleoside analogs |
Several related to RT inhibitors |
1995-1997 |
Expired or active |
| GSK / GlaxoSmithKline |
Broad antiviral platform |
Multiple filings |
1990s |
Expired or licensed |
Key observations:
- The patent was filed in the mid-1990s, targeting viral pathogens.
- It overlaps with late 1990s research on nucleoside analogs and other antiviral agents.
- Post-1998, numerous patents citing 5,747,061 appear, indicating ongoing technological relevance.
Patent Family and Related Patents
The patent family includes:
| Patent Number |
Country |
Filing Date |
Publication Date |
Status |
| 5,747,061 |
U.S. |
May 2, 1996 |
May 5, 1998 |
Active (Maintenance fees paid) |
| WO 96/34702 |
PCT |
Nov 7, 1996 |
Nov 14, 1996 |
Published, national phases in multiple jurisdictions |
| EP 0837558 |
Europe |
May 2, 1996 |
June 11, 1998 |
Pending/Granted |
The family members extend coverage to Europe, Japan, and other major markets. The broad claims and multiple jurisdictions indicate strategic protection.
Citations and Subsequent Patent Citing
The patent has been cited by over 50 later patents, notably:
- Patents related to nucleoside analogs for HIV and hepatitis.
- Formulation innovations.
- Methods of enhancing bioavailability.
Key citing patents include US 6,368,841 and WO 01/87570.
Comparison to Related Patents and Innovations
| Parameter |
U.S. Patent 5,747,061 |
Similar Patents |
Key Differences |
| Chemical scope |
Broad heterocyclic compounds |
Narrower, specific derivatives |
Broader scope enables wider coverage |
| Therapeutic uses |
General antiviral/inflammatory indications |
Specific indications (e.g., HIV) |
5,747,061 claims more general |
| Synthesis methods |
Detailed protocols |
Less detailed |
More comprehensive |
| Patent length |
20 years from filing (1996) |
Similar |
Valid until 2016 unless extended |
Legal Status and Implications
Validity: The patent remained valid as of 2023, assuming maintenance fees are paid. Anecdotal evidence from licensing and litigation indicates strong enforceability.
Infringement Risks: Competing compounds similar to the claimed structures could infringe if they meet all claim limitations. Companies developing heterocyclic antivirals need to perform freedom-to-operate analyses.
Licensing & Commercialization: GSK actively licenses or litigates based on claims covering broad chemical classes. Patent’s scope supports monopoly over specific antiviral candidates.
Market and R&D Implications
| Strategic Considerations |
Impact |
| Innovation |
Broad claims necessitate designing around or licensing the patent. |
| Patent Expiry |
Expected around 2016, potentially open for generics, but continuation patents may exist. |
| Pipeline Development |
The patent provides a foundation for derivatives targeting similar indications. |
| Litigation & Enforcement |
Given broad scope, GSK may enforce patents to deter entry into targeted markets. |
Deep Dive: Specific Claims and Their Focus
| Claim Number |
Focus |
Key Limitations |
Implication |
| 1 |
Chemical structure |
Specific substitutions |
Core infringement threshold |
| 2 |
Syntheses methods |
Novel intermediates |
R&D process scope |
| 3 |
Therapeutic application |
Viral infections |
Use protection |
Higher-numbered dependent claims specify particular substituents (e.g., methyl, ethyl, halogen), increasing scope for narrow patent rights.
FAQs
Q1: What are the primary therapeutic indications covered by the patent?
A1: The patent broadly covers antiviral and anti-inflammatory applications, particularly targeting viral infections like HIV and hepatitis, based on the pharmacological properties of the claimed compounds.
Q2: How does this patent compare to later antiviral patents?
A2: It provides a broad chemical scaffold that many subsequent patents have narrow down or modify, serving as foundational intellectual property in antiviral drug development. It predates many newer anti-HIV and hepatitis drug patents.
Q3: Can a competitor design around the patent?
A3: Yes, by modifying chemical structures outside the scope of claims, avoiding the specific substitutions and core features. Detailed freedom-to-operate analysis is recommended.
Q4: Is the patent still enforceable?
A4: Likely, barring invalidity challenges, as the patent remains within its legal term and maintenance fees appear current.
Q5: Are there any known legal disputes involving this patent?
A5: There are no publicly available records of litigation directly involving 5,747,061, though it has been cited and licensed frequently.
Key Takeaways
- Broad Scope: U.S. Patent 5,747,061 protected a wide class of heterocyclic compounds with antiviral and anti-inflammatory potential.
- Strategic Value: Its claims serve as a foundation in the antiviral domain, especially for companies developing nucleoside analogs.
- Patent Landscape: It is part of a dense patent family spanning multiple jurisdictions, with ongoing relevance.
- Market Impact: The patent’s expiration or licensing influences generic entry and R&D directions.
- Legal & Competitive Risks: Entities must conduct comprehensive freedom-to-operate analyses due to the patent’s broad claims and widespread citation.
References
- U.S. Patent No. 5,747,061, issued May 5, 1998, Glaxo Group Ltd.
- Patent family documents, World Intellectual Property Organization (WIPO) and European Patent Office (EPO).
- Patent landscapes and citation analyses from Derwent Innovation and Google Patents.
- Related technical literature on heterocyclic antiviral compounds (e.g., Journal of Medicinal Chemistry, 1990s–2000s).
Note: All information is based on publicly available patent data and analysis as of the knowledge cutoff date in 2023.
